AGL 40.00 Decreased By ▼ -0.16 (-0.4%)
AIRLINK 129.53 Decreased By ▼ -2.20 (-1.67%)
BOP 6.68 Decreased By ▼ -0.01 (-0.15%)
CNERGY 4.63 Increased By ▲ 0.16 (3.58%)
DCL 8.94 Increased By ▲ 0.12 (1.36%)
DFML 41.69 Increased By ▲ 1.08 (2.66%)
DGKC 83.77 Decreased By ▼ -0.31 (-0.37%)
FCCL 32.77 Increased By ▲ 0.43 (1.33%)
FFBL 75.47 Increased By ▲ 6.86 (10%)
FFL 11.47 Increased By ▲ 0.12 (1.06%)
HUBC 110.55 Decreased By ▼ -1.21 (-1.08%)
HUMNL 14.56 Increased By ▲ 0.25 (1.75%)
KEL 5.39 Increased By ▲ 0.17 (3.26%)
KOSM 8.40 Decreased By ▼ -0.58 (-6.46%)
MLCF 39.79 Increased By ▲ 0.36 (0.91%)
NBP 60.29 No Change ▼ 0.00 (0%)
OGDC 199.66 Increased By ▲ 4.72 (2.42%)
PAEL 26.65 Decreased By ▼ -0.04 (-0.15%)
PIBTL 7.66 Increased By ▲ 0.18 (2.41%)
PPL 157.92 Increased By ▲ 2.15 (1.38%)
PRL 26.73 Increased By ▲ 0.05 (0.19%)
PTC 18.46 Increased By ▲ 0.16 (0.87%)
SEARL 82.44 Decreased By ▼ -0.58 (-0.7%)
TELE 8.31 Increased By ▲ 0.08 (0.97%)
TOMCL 34.51 Decreased By ▼ -0.04 (-0.12%)
TPLP 9.06 Increased By ▲ 0.25 (2.84%)
TREET 17.47 Increased By ▲ 0.77 (4.61%)
TRG 61.32 Decreased By ▼ -1.13 (-1.81%)
UNITY 27.43 Decreased By ▼ -0.01 (-0.04%)
WTL 1.38 Increased By ▲ 0.10 (7.81%)
BR100 10,407 Increased By 220 (2.16%)
BR30 31,713 Increased By 377.1 (1.2%)
KSE100 97,328 Increased By 1781.9 (1.86%)
KSE30 30,192 Increased By 614.4 (2.08%)

Drug importers have been forced to stop importing most of the foreign medicines owing to massive depreciation of Pakistani rupee against the US dollar and are of the view that imported drugs have now become too expensive to earn profit in local market.

According to drug market sources, dollar value against Pakistani currency during 2018-19 witnessed an increase of 50 percent while the government is not allowing increase in prices of imported drugs.

Since 2018-19, Pak rupee exchange rate against dollar has gone up from Rs 106 to around Rs 155 while prices of imported drugs are not revised and as a result, importers have stopped importing some medicines. Moreover, almost 40 percent imported drugs in Pakistan are coming from India and Indian companies are not willing to sell their products to Pakistanis. Resultantly, import of these drugs from other markets such as Germany puts additional costs on Pakistani buyers, they added. An official of Drug Regulatory Authority of Pakistan (DRAP) said that presently, drug inspectors have intensified checking of unregistered medicines being sold at pharmacies/chemists. Due to this exercise, shopkeepers have stopped keeping unregistered imported medicines which are smuggled into the country.

A senior official of Pakistan Pharmaceutical Manufacturing Association (PPMA) told Business Recorder that Pakistan at present is not only facing serious shortage of cancer related medicines but supply of drugs being used for the treatment of other diseases is also short owing to government policies and rupee depreciation. For example, imported vaccines for flu and rabies and Furolin, an imported medicine to treat urinary tract infection, are not available in market.

The prices of injections used for CT scan contrast and MRI contrast have been increased from Rs 1,650-2,000 to Rs 4,500 and above. Similarly, import of Nutraceuticals Skin Active skincare products has almost been stopped.

The official said that local drug manufacturers are also facing serious problems owing to regular increase in gas/electricity prices and other input costs including labor. However, the government wants them to sell the products at fixed rates. The PPMA official said that globally up to 105-110 molecules' prices are regulated and rest of the product prices are left on the market forces, while in Pakistan prices of each and every product is regulated.

Copyright Business Recorder, 2019

Comments

Comments are closed.